Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWuxi Hisky Medical Technology Co Ltd
About this trial
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
UAP were measured based on iLivTouch
Willing to attend this study and able to provide the written informed consent.
Disqualifiers
Other types of diabetes
Patients unable to receive regular follow-up
Trial population
Patients with T2DM
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
Procedure/SurgeryEligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
Treatment groups
2,900 Participants
are divided into 1 treatment groupGroup A: Patients who diagnosed as T2DM1 intervention
Trial outcomes
Primary outcomes
1
The proportion of patients with MAFLD in the T2DM population screened by UAP with iLivTouch
To explore the prevalence and clinical characteristics of MAFLD in patients with T2DM
Time frame
12 months2
Correlation between UAP and insulin resistance
To explore the correlation between UAP and insulin resistance in patients with T2DM
Time frame
12 months3
Analysis of risk factors for clinical outcomes in patients with T2DM
To analyze risk factors affecting clinical outcomes in patients with T2DM
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Wuxi Hisky Medical Technology Co Ltd
Lead sponsor
Zhongda Hospital
Collaborator
Suzhou Municipal Hospital
Collaborator
Suzhou Fifth People's Hospital
Collaborator
Xuzhou Mining Group General Hospital
Collaborator
Nantong First People's Hospital
Collaborator
Changzhou Second People's Hospital
Collaborator
Huaian Second People's Hospital
Collaborator
Huaian Hospital
Collaborator
Taizhou Jiangyan Traditional Chinese Medicine Hospital
Collaborator
Yangzhou Jiangdu People's Hospital
Collaborator
Huaian Xuyi County People's Hospital
Collaborator
Source ClinicalTrials.gov